BATM Advanced Communications Ld Notice of AGM and Directorate Change (2727G)
November 05 2018 - 1:00AM
UK Regulatory
TIDMBVC
RNS Number : 2727G
BATM Advanced Communications Ld
05 November 2018
LEI: 213800FLQUB9J289RU66
5 November 2018
BATM Advanced Communications Limited
("BATM" or "the Group")
Notice of AGM and Directorate Change
BATM Advanced Communications Limited (LSE: BVC), a leading
provider of real-time technologies for networking solutions and
medical laboratory systems, gives notice that the Annual General
Meeting ("AGM") of the Group is to be held at 10.00am GMT on
Wednesday 28 November 2018 at the offices of Luther Pendragon, 48
Gracechurch Street, London, EC3V 0EJ, England.
Among the resolutions to be voted on at the AGM are the proposed
appointments of Prof. Ari Shamiss and Prof. Varda Shalev as
external directors of the Group, as required under Israeli law, for
three-year periods commencing upon the approval of the resolution
at the AGM. Prof. Shamiss and Prof. Shalev will be replacing Dr.
Avigdor Shafferman and Mrs Orna Pollack respectively, whose
three-year tenures as external directors expire and who retire from
the Board of Directors.
Further information on the resolutions can be found in the
Notice of AGM circular that has, along with forms of proxy and
direction, been posted to shareholders and is available on BATM's
website at: www.batm.com.
Proposed Director Appointments
Prof. Ari Shamiss
Prof. Ari Shamiss, aged 60, is a medical expert with over 35
years' experience in the healthcare and biotechnology industries.
He is currently CEO of Assuta Medical Centers, a network of eight
hospitals and medical centres in Israel. Prior to assuming this
position in 2016, Prof. Shamiss spent over 30 years at the Sheba
Medical Center, which is the largest hospital in Israel and where a
significant proportion of the country's clinical research is
conducted, in various roles and most latterly being CEO of the
Sheba General Hospital from 2005 to 2016.
He has also served in advisory roles at various private and
public organisations, including academic institutions such as being
a Senior Lecturer at Tel Aviv University School of Medicine and a
Senior Researcher at Harvard Business School. He has provided
business advisory and consultancy to companies such as Quantason
LLC, a California-based med-tech company that has developed a
next-generation ultrasound technology, and currently BioGaming, an
Israeli provider of an artificial intelligence solution to enhance
physical therapy to improve rehabilitation outcomes. He also sits
on the advisory board of the Sheba Cancer Research Center Council
and the Gertner Institute for Epidemiology and Health Policy
Research.
Prof. Varda Shalev
Prof. Varda Shalev (née Borst), aged 59, is a specialist in
epidemiology, medical informatics and predictive analytics in
community healthcare. She currently holds the position of Director
of the Morris Kahn & Maccabi Institute for Health Research and
Innovation and is an active primary care physician in Maccabi
Healthcare Services in Tel Aviv, where she has worked for eight
years. She has pioneered the development of multiple disease
registries to support chronic disease management. In addition, she
is a faculty member at the Tel Aviv University School of Public
Health and sits on the advisory board of several med-tech
businesses, including Belongtail Ltd, Ibex Medical Analytics Ltd,
NUVO Inc and Valera Health, and is a director of the Israel
Advanced Technology Industries, a non-profit organisation. She is a
director and co-owner of Dr. Benjamin Shalev Eye Physician Ltd,
through which she provides physician services.
She holds an MD degree from Ben-Gurion University Medical School
in Israel, and completed her residency in family medicine and
earned a Master of Public Health Administration at Clark University
in the US. She then completed a two-year fellowship in medical
informatics at the Johns Hopkins University Hospital in the US.
Prof. Shalev has authored or co-authored over 200 publications in
peer-reviewed medical journals.
There is no further information required to be disclosed in
relation to Prof. Shamiss or Prof. Shalev pursuant to Listing Rule
9.6.13 and neither of them has any beneficial interest in BATM's
ordinary shares.
Enquiries:
BATM Advanced Communications
Dr Zvi Marom, Chief Executive Officer +972 9866 2525
-----------------
Moti Nagar, Chief Financial Officer
-----------------
Shore Capital
-----------------
Mark Percy, Anita Ghanekar +44 20 7408 4050
-----------------
Luther Pendragon
-----------------
Harry Chathli, Claire Norbury +44 20 7618 9100
-----------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLFFEVLFLSIIT
(END) Dow Jones Newswires
November 05, 2018 02:00 ET (07:00 GMT)
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From Apr 2024 to May 2024
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From May 2023 to May 2024